SkelGen: A general tool for structure-based de novo ligand design

Expert Opinion on Drug Discovery

Volumn 1, Issue 2, 2006, Pages 179-189

  Dean, Philip M ^a   Firth Clark, Stuart ^a   Harris, William ^a   Kirton, Stewart B ^a   Todorov, Nikolay P ^a  

^a De Novo Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250167837     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.2.179     Document Type: Review

References (55)

1. ROCHE O, SCHNEIDER P, ZUEGGE J et al.: Development of a virtual screening method for identification of frequent hitters in compound libraries. J. Med. Chem. (2002) 45:137-142.
2. OPREA TI, MATTER H: Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. (2004) 8:349-358.
3. HANN MM, OPREA TI: Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. (2004) 8:255-263.
4. LUNDQVIST T: The devil is in the details - driving early drug discovery forward with biophysical experimental methods. Curr. Opin. Drug Discovery Dev. (2005) 8(4):513-519.
5. HOSFIELD D, PALAN J, HILGERS M, SCHEIBE D, McREE DE, STEVENS RC: A fully integrated protein crystallization platform for small-molecule drug discovery. J. Struct. Biol. (2003) 142:207-217.
6. HARTSHORN MJ, MURRAY CW, CLEASBY A, FREDERICKSON M, TICKLE IJ, JHOTI H: Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. (2005) 48(2):403-413.
7. BOHACEK RS, McMARTIN C: Modern computational chemistry and drug discovery: structure generating programs. Curr. Opin. Chem. Biol. (1997) 1(2):157-161.
8. HAN Q, DOMINGUEZ C, STOUTEN PFW et al.: Design, synthesis and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. J. Med. Chem. (2000) 43(23):4398-4415.
9. RIPKA AS, SATYSHUR KA, BOHACEK RS, RICH DH: Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Org. Lett. (2001) 3(15):2309-2312.
10. HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of CDK4 inhibitors: new de novo design strategy and library design. J. Med. Chem. (2001) 44(26):4615-4627.
11. PISABARRO MT, ORTIZ AR, PALOMER A et al.: Rational modification of human synovial fluid phospholipase A2 inhibitors. J. Med. Chem. (1994) 37:337-341.
12. GRZYBOWSKI BA, ISHCHENKO AV, KIM C-Y et al.: Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc. Natl. Acad. Sci. USA (2002) 99(3):1270-1273.
13. GEHLHAAR DK, MOERDER KE, ZICHI D, SHERMAN CJ, OGDEN RC, FREER ST: De novo design of enzyme inhibitors by Monte Carlo ligand generation. J. Med. Chem. (1995) 38:466-472.
14. VINKERS HM, DE JONGE MR, DAEYAERT FFD et al.: SYNOPSIS: SYNthesize and OPtimize System In Silico. J. Med. Chem. (2003) 46:2765-2773.
15. TODOROV NP, DEAN PM: Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J. Comp.-Aided Mol. Des. (1997) 11: 175-192.
16. TODOROV NP, DEAN PM: Computational ligand design by free energy minimization. In: Biological Physics. Frauenfelder H, Hummer G, Garcia R (Eds), American Institute of Physics, USA (1999) .
17. STAHL M, TODOROV NP, JAMES T, MAUSER H, BÖ;HM HJ, DEAN PM: A validation study of the practical use of de novo design. J. Comput.-Aided Mol. Des. (2002) 16:459-478.
18. STAHL M, RAREY M: Detailed analysis of scoring functions for virtual screening. J. Med. Chem. (2001) 44:1035-1042.
19. LEWELL XQ, JUDD DB, WATSON SP, HANN MM: RECAP - Retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comp. Sci. (1998) 38:511-522.
20. HANSSON T, MARELIUS J, ÅQVIST J: Ligand binding affinity prediction by linear interaction energy methods. J. Comput.-Aided Mol. Des. (1998) 12(1):27-35.
21. HUANG D, CAFLISCH A: Efficient evaluation of binding free energy using continuum electrostatics solvation. J. Med. Chem. (2004) 47:5791-5797.
22. KUHN B, GERBER P, SCHULTZ-GASCH T, STAHL M: Validation and use of the MM-PBSA approach for drug discovery. J. Med. Chem. (2005) 48(12):4040-4048.
23. TODOROV NP, BNEMANN CL, ALBERTS IL: De novo ligand design to an ensemble of protein structures. Proteins: structure, function and bioinformatics. (2006) (In Press).
24. ALBERTS IL, TODOROV NP, KLLBLAD P, DEAN PM: Ligand docking and design in a flexible receptor site. QSAR and Comb. Sci. (2005) 24:503-507.
25. ALBERTS IL, TODOROV NP, DEAN PM: Receptor flexibility in de novo ligand design and docking. J. Med. Chem. (2005) 48:6585-6596.
26. DUNBRACK RL Jr, KARPLUS M: Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J. Mol. Biol. (1993) 230(2):543-574.
27. XIANG Z, HONIG B: Extending the accuracy limits of prediction for side-chain conformations. J. Mol. Biol. (2001) 311(2):421-430.
28. ERLANSON DA, McDOWELL RS, OBRIEN T: Fragment-based drug discovery. J. Med. Chem. (2004) 47:3463-3482.
29. BOEHM H-J, BOEHRINGER M, BUR D et al.: Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. (2000) 43:2664-2674.
30. FIRTH-CLARK S, TODOROV NP, ALBERTS IL, WILLIAMS A, JAMES T, DEAN PM: Exhaustive de novo design of low-molecular-weight fragments against the ATP-binding site of DNA-gyrase. J. Chem. Inf. Model (2006) 46(3):1168-1173.
31. REECE RJ, MAXWELL A: DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol. (1991) 26:335-375.
32. BRINO L, URZHUMTSEV A, MOUSLI M et al.: Dimerization of Escherichia coli DNA-gyrase B provides a structuralmechanism for activating the ATPase catalytic center. J. Biol. Chem. (2000) 275:9468-9475.
33. FIRTH-CLARK S, WILLEMS HMG, WILLIAMS A, HARRIS W: Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen. J. Chem. Inf. Model. (2006) 46(2):642-647.
34. RAREY M, KRAMER B, LENGAUER T, KLEBE G: A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. (1996) 261(3):470-489.
35. LORBER DM, SCHOICHET BK: Flexible ligand docking using conformational ensembles. Protein. Sci. (1998) 7:938-950.
36. TOTROV M, ABAGYAN R: Flexible protein-ligand docking by global energy optimisation in internal coordinates. Proteins Structure Function and Genetics (1997) 29(S1):215-220.
37. FRADERA X, KNEGTEL RMA, MESTRES J: Similarity-driven flexible ligand docking. Proteins Structure Function and Genetics (2000) 40(4):623-636.
38. MAKINO S, EWING TJA, KUNTZ ID: DREAM++: flexible docking program for virtual combinatorial libraries. J. Comput.- Aided Mol. Des. (1999) 3(5):513-532.
39. BUDIN N, MAIEUX N, CAFLISCH A: fragment-based flexible ligand docking by evolutionary optimisation. Biol. Chem. (2001) 382:1365-1372.
40. ZHU J, FAN H, LUI H, SHI Y: Structure-based ligand design for flexible proteins: Application of new F-DycoBlock. J. Comput.-Aided Mol. Des. (2001) 15(11):979-996.
41. CARLSON HA, MCCAMMON JA: Accommodating protein flexibility in computational drug design. Mol. Pharmacol. (2000) 57(2):213-218.
42. ANDERSON AC, ONEIL RH, SURTI TS, STROUD RM: Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking. Chem. Biol. (2001) 8:445-457.
43. BRZOZOWSKI AM, PIKE AC, DAUTER Z et al.: Molecular basis of agonism and antagonism in the estrogen receptor. Nature (1997) 389:753-758.
44. KIRTON SB, WILLEMS HMG, WILLIAMS A, FIRTH-CLARK S: Manuscript in preparation.
45. CLARK M, GUARNIERI F, SHKURKO I, WISEMAN J: Grand canonical Monte Carlo simulation of ligand-protein binding. J. Chem. Inf. Model (2006) 46:231-242.
46. VON LILIENFELD OA, LINS RD, ROTHLISBERGER U: Variational particle number approach for rational compound design. Phys. Rev. Lett. (2005) 95:153002.
47. MARRONE TJ, BRIGGS JM, McCAMMON JA: Structure-based drug design: computational advances. Ann. Rev. Pharmacol. Toxicol. (1997) 37:71-90.
48. HUANG D, LTHI U, KOLB P et al.: Discovery of cell-permeable non-peptide inhibitors of α-secretase by high-throughput docking and continuum electrostatics calculations. J. Med. Chem. (2005) 48(16):5108-5111.
49. COZZA G, BONVINI P, ZORZI E et al.: Identification of ellagic acid as a potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J. Med. Chem. (2006) 49(8):2363-2366.
50. HOPKINS AL, MASON JS, OVERINGTON JP: Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. (2006) 16:127-136.
51. KIM RB: Transporters and drug discovery: why, when and how. Mol. Pharm. (2006) 3(1):26-32.
52. MORPHY R, RANKOVIC Z: Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. (2005) 48(21):6523-43.
53. DEAN PM: Computer-aided design of small molecules for chemical genomics. In: Methods Molecular Biology Chemical Genomics: Reviews and Protocols. Zanders ED (Ed), Humana Press, Inc., Totowa, USA (2005) 310:25-39.
54. WATTS P, HASWELL SJ: The application of micro-reactors for small scale organic synthesis. Chem. Eng. Technol. (2005) 28:290-301.
55. http://www.locusdiscovery.com/science/projects/p38.php Locus white paper covering design of p38 inhibitors (2005).